TheRoleofCirculatingBiomarkersinPost-COVID-19 Patients
The new coronavirus infection has made significant adjustments to the condition of patients already suffering from cardiovascular diseases. Similar mechanisms of fibrosis in patients with severe COVID-19 and heart failure have drawn attention to inflammatory biomarkers. The severe cytokine storm that is characteristic of COVID-19 is critical to understanding the outcome of the disease. In severe COVID-19, higher levels of interleukin-2, interleukin-6, interleukin-10, monocyte chemotactic protein-1 (MCP-1), and tumor necrosis factor-α (TNF-α) were noted than in patients with mild to moderate form of the disease. Elevated levels of MCP-1 in severe COVID-19 suggest that its secretion may play a key role in the reactive inflammatory process associated with COVID-19. It has been established that IL-10 and MCP-1 are predictors of the severity of COVID-19 disease and the risk of death in such patients. Matrix metalloproteinases (MMPs) are also involved in the development of lung pathology and may act as an early indicator of respiratory failure in patients with COVID-19. In this review, biomarkers of inflammation, such as MMP, tissue inhibitor of matrix metalloproteinase-1, interleukins, MCP-1, are considered for their ability to serve as objective markers for early diagnosis and prognosis of the development of cardiovascular complications in patients who have undergone COVID-19.
Osipova O.A., Shepel R.N., Karutskaya O.A., Komisov A.A., Demko V.V., Belousova O.N., Chupakha M.V. 2023. The Role of Circulating Biomarkers in Post-COVID-19 Patients. Challenges in Modern Medicine. 46 (3): 231–244 (in Russian). DOI: 10.52575/2687-0940-2023-46-3-231-244
While nobody left any comments to this publication.
You can be first.
Alekseeva E.I., Tepaev R.F., Shilkrot I.Yu., Dvoryakovskaya T.M., Surkov A.G., Criulin I.A.. COVID-19-induced "cytokine storm" is a special form of macrophage activation syndrome. Bulletin of RAMN. 2021. 76 (1). S. 51–66. doi: https://doi.org/10.15690/vramn1410 (in Russian).
Bazdyrev E.D. Coronavirus infection is an urgent problem of the XXI century. Complex problems of cardiovascular diseases. 2020; 9 (2): 6–16. doi:10.17802/2306-1278-2020-9-2-6-16 (in Russian).
Borodulina E.A., Vasneva Zh.P., Vdoushkina E.S., Borodulin B.E., Povalyaeva L.V. Features of hematological and hemostasiological parameters in patients with COVID-19 coronovirus infection and community-acquired pneumonia. Acta Biomedica Scientifica. 2021. 6 (1): 40–47. doi: 10.29413/ABS.2021-6.1.6 (in Russian).
Bunova S.S., Okhotnikova P.I., Skirdenko Yu.P., Nikolaev N.A., Osipova O.A., Zhernakova N.I. COVID-19 and cardiovascular comorbidity: the search for new approaches to reduce mortality. Cardiovascular therapy and prevention. 2021; 20 (4): 2953. doi:10.15829/1728-8800-2021-2953 (in Russian).
Grigorieva N.Yu., Sinichkina A.A., Samolyuk M.O. et al. // Russian Journal of Cardiology. – 2022. – Vol. 27, No. 3. – pp. 67–73. doi: 10.15829/1560-4071-2022-4846 (in Russian).
Zolnikova O.Yu., Svistunov A.A., Ivashkin V.T. SARS-COV-2: Immune response, structural changes, main therapeutic strategies. Human ecology 2021. No. 1. P. 4–10. doi: 10.33396/1728-0869-2021-1-4-10 (in Russian).
Kostyuk S.A., Simirsky V.V., Gorbich Yu.L., Anisko L.A., Poluyan O.S. Cytokine storm in COVID-19. Magazine. International reviews: Clinical practice and health. No. 1. 2021. P. 41–52 (in Russian).
Pecherina T.B., Kutikhin A.G. Biomarkers of myocardial fibrosis and their genetic regulation in patients with heart failure. Russian journal of cardiology. 2020; 25 (10): 3933. https://doi.org/10.15829/1560-4071-2020-3933 (in Russian).
Potapnev M.P. Cytokine storm: causes and consequences. Immunology. 2021; 42 (2): 175–188. doi: 10.33029/0206-4952-2021-42-2-175-188 (in Russian).
Rassokhin V.V., Samarina A.V., Belyakov N.A., Trofimova T.N., Lukina O.V., Gavrilov P.V., Grinenko O.A. Epidemiology, clinic, diagnosis, assessment of the severity of COVID-19 disease, taking into account comorbidity. HIV infection and immunosuppression. 2020; 12 (2): 7–30. https://doi.org/10.22328/2077-9828-2020-12-2-7-30 (in Russian).
Sudzhaeva O.A. The significance of cardiometabolic risk factors during the COVID-19 pandemic: a review of the consensus of experts of the European Society of Cardiology / O.A. Sudzhaeva // Recipe. – 2022. – Vol. 25, No. 4. – pp. 418–431. doi: 10.34883/PI.2022.25.4.006 (in Russian).
Sushentseva N.N., Popov O.S., Apalko S.V., etc. COVID-19 biobank: features of the cytokine profile. Cardiovascular therapy and prevention. – 2020. – Vol. 19, No. 6. – pp. 191–195. doi: 10.15829/1728-8800-2020-2729 (in Russian).
Abers M.S., Delmonte O.M., Ricotta E.E., Fintzi J. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight. 2020. doi: 10.1172/jci.insight.144455
Bajpai G., Bredemeyer A., Li W., Zaitsev K., Koenig A.L., Lokshina I., Mohan J., Ivey B., Hsiao H.M., Weinheimer C., Kovacs A., Epelman S., Artyomov M., Kreisel D., Lavine K.J. Tissue Resident CCR2- and CCR2+ Cardiac Macrophages Differentially Orchestrate Monocyte Recruitment and Fate Specification Following Myocardial Injury. Circ. Res. 2019 Jan 18; 124 (2): 263–278. doi: 10.1161/CIRCRESAHA.118.314028
Brusa S., Terracciano D., Bruzzese D., Fiorenza M., Stanziola L., Pinchera B., Valente V., Gentile I., Cittadini A., Mormile I., Mormile M., Portella G. Circulating tissue inhibitor of metalloproteinases 1 (TIMP-1) at COVID-19 onset predicts severity status. Front Med (Lausanne). 2022 Nov 29; 9: 1034288. doi: 10.3389/fmed.2022.1034288
Castaño M., Tomás-Pérez S., González-Cantó E., Aghababyan C., Mascarós-Martínez A., Santonja N., Herreros-Pomares A., Oto J., Medina P., Götte M., Mc Cormack B.A., Marí-Alexandre J.,
Gilabert-Estellés J. Neutrophil Extracellular Traps and Cancer: Trapping Our Attention with Their Involvement in Ovarian Cancer. Int. J. Mol. Sci. 2023 Mar 22; 24 (6): 5995. doi: 10.3390/ijms24065995
Chen B., Frangogiannis N.G. Chemokines in Myocardial Infarction. J. Cardiovasc. Transl. Res. 2021 Feb; 14 (1): 35–52. doi: 10.1007/s12265-020-10006-7
Chen B., Huang S., Su Y., Wu Y.J., Hanna A., Brickshawana A., Graff J., Frangogiannis N.G. Macrophage Smad3 Protects the Infarcted Heart, Stimulating Phagocytosis and Regulating Inflammation. Circ. Res. 2019, 125: 55–70. doi: 10.1161/CIRCRESAHA.119.315069
Conti P., Ronconi G., Caraffa A., Gallenga C., Ross R., Frydas I. et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J. Biol. Regul. Homeost. Agents. 2020 March-April; 34 (2): 327–331. doi: 10.23812/CONTI-E. PMID: 32171193
De Vita A., Franceschi F., Covino M. Increased Thrombotic Risk in COVID-19: Evidence and Controversy. J. Clin. Med. 2023 Jul 1; 12 (13): 4441. doi: 10.3390/jcm12134441
Dhar S.K., Vishnupriyan K., Damodar S., Gujar S., Das M. IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression. medRxiv. 2020; 1843: 2563.
Diao B., Wang C., Tan Y., Chen X., Liu Y., Ning L. et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19) Front Immunol. 2020; 11: 827. doi: 10.3389/fimmu.2020.00827
Frangogiannis N.G. Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol. Aspects. Med. 2019 Feb; 65: 70–99. doi: 10.1016/j.mam.2018.07.001
Frisoni P., Neri M., Alfieri L. et al. Cytokine storm and histopathological findings in 60 cases of COVID-19-related death: from viral load research to immunohistochemical quantification of major players IL-1β, IL-6, IL-15 and TNF-α // Forensic Science, Medicine, and Pathology. – 2022 Mar; 18 (1): 4–19. doi: 10.1007/s12024-021-00414-9
Furuya Y., Satoh T., Kuwana M. Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension. Int. J. Rheumatol. 2010; 2010: 720305. doi: 10.1155/2010/720305
Giannis D., Ziogas I.A., Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J. Clin. Virol. 2020; 127: 104362.
Goyal P., Reshetnyak E., Khan S., Musse M., Navi B.B., Kim J., Allen L.A., Banerjee S., Elkind M.S.V., Shah S.J., Yancy C., Michos E.D., Devereux R.B., Okin P.M., Weinsaft J.W., Safford M.M. Clinical Characteristics and Outcomes of Adults With a History of Heart Failure Hospitalized for COVID-19. Circ Heart Fail. 2021 Sep; 14 (9): e008354. doi: 10.1161/CIRCHEARTFAILURE.121.008354
Hazra S., Chaudhuri A.G., Tiwary B.K., Chakrabarti N. Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: a network-based meta-analysis. Life Sci. 2020; 257 doi: 10.1016/j.lfs.2020.118096
Heidt T., Courties G., Dutta P., Sager H.B., Sebas M., Iwamoto Y., Sun Y., Da Silva N., Panizzi P., van der Laan A.M., Swirski F.K., Weissleder R., Nahrendorf M. Differential contribution of monocytes to heart macrophages in steady-state and after myocardial infarction. Circ. Res. 2014 Jul 7; 115 (2): 284–95. doi: 10.1161/CIRCRESAHA.115.303567
Hu B., Huang S., Yin L. The cytokine storm and COVID-19. J. Med. Virol. 2021 Jan; 93 (1): 250–256. doi: 10.1002/jmv.26232
Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497–506. doi: 10.1016/S0140-6736(20)30183-5
Liu J., Li S., Liu J., Liang B., Wang X., Wang H., Li W., Tong Q., Yi J., Zhao L., Xiong L., Guo C., Tian J., Luo J., Yao J., Pang R., Shen H., Peng C., Liu T., Zhang Q., Wu J., Xu L., Lu S., Wang B., Weng Z., Han C., Zhu H., Zhou R., Zhou H., Chen X., Ye P., Zhu B., Wang L., Zhou W., He S., He Y., Jie S., Wei P., Zhang J., Lu Y., Wang W., Zhang L., Li L., Zhou F., Wang J., Dittmer U., Lu M., Hu Y,, Yang D,, Zheng X. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020 May; 55: 102763. doi: 10.1016/j.ebiom.2020.102763
Metzemaekers M., Cambier S., Blanter M., Vandooren J., de Carvalho A.C., Malengier-Devlies B. et al. Kinetics of peripheral blood neutrophils in severe coronavirus disease 2019. Clin. Transl. Immunol. (2021) 10: e1271. 10.1002/cti2.1271.
Nalbandian A., Sehgal K., Gupta A., Post-acute COVID-19 syndrome. Nat. Med. 2021 Apr; 27 (4): 601–615. doi: 10.1038/s41591-021-01283-z
Nappi F., Bellomo F., Avtaar Singh S.S. Worsening Thrombotic Complication of Atherosclerotic Plaques Due to Neutrophils Extracellular Traps: A Systematic Review. Biomedicines. 2023 Jan 2; 11 (1): 113. doi: 10.3390/biomedicines11010113
Nasr El-Din A., Ata K.A.E., Abdel-Gawad A.R., Fahmy N.F. Impact of High Serum Levels of MMP-7, MMP-9, TGF-β and PDGF Macrophage Activation Markers on Severity of COVID-19 in Obese-Diabetic Patients. Infect Drug Resist. 2021 Sep 28; 14: 4015–4025. doi: 10.2147/IDR.S329004
Pertiwi K.R., de Boer O.J., Mackaaij C., Pabittei D.R., de Winter R.J., Li X., van der Wal A.C. Extracellular traps derived from macrophages, mast cells, eosinophils and neutrophils are generated in a time-dependent manner during atherothrombosis. J. Pathol. 2019 Apr; 247 (4): 505–512. doi: 10.1002/path.5212
Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan. China Intensive Care Med. 2020; 46 (5): 846–848. doi: 10.1007/s00134-020-05991-x
Sindelar M., Stancliff E., Schweiger-Haber M. et al. Longitudinal metabolomics of human blood plasma reveals prognostic markers of the severity of COVID-19 disease. Representative of Cell Med. 2021; 2 (8): 100369. doi: 10.1016/j.xcrm.2021.100369
Singh B., Ghosh N., Saha D., Sarkar S., Bhattacharyya P., Chaudhury K. Effect of doxycyline in chronic obstructive pulmonary disease – An exploratory study. Pulm. Pharmacol. Ther. 2019; 58: 101831. doi: 10.1016/j.pupt.2019.101831
Siu K.L., Yuen K.S., Castano-Rodriguez C., Ye Z.W., Yeung M.L., Fung S.Y. et al. Severe acute respiratory syndrome Coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC. FASEB J. 2019; 33 (8): 8865–8877. doi: 10.1096/fj.201802418R
Subramaniam S., Scharrer I. Procoagulant activity during viral infections. Front. Biosci. 2018; 23: 1060–1081.
Tan X., Hu L., Shu Z., Chen L., Li X., Du M., Sun D., Mao X., Deng S., Huang K. et al.: Role of CCR2 in the Development of Streptozotocin-Treated Diabetic Cardiomyopathy. Diabetes 2019, 68: 2063–2073. doi: 10.2337/db18-1231
Trihandini I., Muhtar M., Karunia Sakti D.A., Erlianti C.P. The effect of long-haul COVID-19 toward domains of the health-related quality of life among recovered hospitalized patients. Front. Public. Health. 2023 Aug 3; 11: 1068127. doi: 10.3389/fpubh.2023.1068127
Ueland T., Holter J., Holten A. et al. Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure. The Journal of Infection. 2020; 81: e41–3. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320854/.
Ueland T., Holter J., Holten A., Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure. J. Infect. 2020; 81: e41–e43. doi: 10.1016/j.jinf.2020.06.061
Wang J., Jiang M., Chen H., Montaner L.J. Cytokine storm and leukocyte changes in mild and severe SARS-Cov-2 infection: overview of 3939 COVID-19 patients in China and new concepts of pathogenesis and therapy. J. Leukocyte biology. 2020; 108 (1): 17–41. doi:10.1002/JLB.3COVR0520-272R
Willeford A., Suetomi T., Nickle A., Hoffman H.M., Miyamoto S., Heller Brown J. CaMKIIdelta-mediated inflammatory gene expression and inflammasome activation in cardiomyocytes initiate inflammation and induce fibrosis. J.C.I. Insight. 2018. 3. doi: 10.1172/jci.insight.97054
Williamson E.J., Walker A.J., Bhaskaran K. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020; 584 (7821): 430–436. doi: 10.1038/s41586-020-2521-4
Wynn T.A., Vannella K.M. Macrophages in Tissue Repair, Regeneration, and Fibrosis. Immunity. 2016 Mar 15; 44 (3): 450–462. doi: 10.1016/j.immuni.2016.02.015
Zhang Q., Bastard P., Liu Z., Le Pen J., Moncada-Velez M., Chen J. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020; 370 (6515): eabd4570. doi: 10.1126/science. abd4570.
The work was carried out without external sources of funding.